Helsinn Archives | Page 2 of 2

Home / Posts tagged Helsinn (Page 2)

Helsinn and Mundipharma China Pharmaceutical Jointly Announce NMPA’s Approval of the Oral Formulation of Akynzeo® in China

Lugano, Switzerland, and Beijing, China, Sept. 16 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and Mundipharma China Pharmaceutical, the market leader in pain management, today jointly announce that the National Medical Products Administration (NMPA) has approved the oral formulation of Akynzeo® for the treatment of chemotherapy-induced nausea and [...]

Helsinn Signs Exclusive Distribution and License Agreements with Blanver and Varifarma for Pracinostat in South America

Lugano, Switzerland, São Paulo, Brazil, and Buenos Aires, Argentina, Sept. 2 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, together with Blanver Farmoquímica e Farmacêutica S.A., a Brazilian company focused on innovative products with high quality medicines and active pharmaceutical ingredients, committed to expand patient access, and Laboratorio Varifarma [...]

Helsinn to Co-support a Satellite Symposium on Current and Emerging Treatments of Acute Myeloid Leukemia (AML) at 24th European Hematology Association (EHA) Congress

Lugano, Switzerland, Jun. 12 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it will co-support a satellite symposium around current and emerging treatment options for Acute Myeloid Leukemia (AML) at the 24th European Hematology Association (EHA) Congress. The symposium, titled “Current and Emerging Treatment Options in AML: [...]

Helsinn Group Announces Upcoming Presentation of Phase 3b Data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019

Lugano, Switzerland, May 31 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the data on the intravenous (IV) formulation of NEPA (Akynzeo®) will be presented as poster at the American Society of Clinical Oncology (ASCO) Congress in June 2019 on the poster session Symptoms and Survivorship. [...]

Helsinn Nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association

Switzerland, May 7 (Korea Bizwire) - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it is one of the companies to have been nominated as one of the Swiss Biotech Association’s Biotech Success Stories for the period 2019/2020. Helsinn was nominated alongside Actelion and Debiopharm, as well as three [...]

Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting

LUGANO, Switzerland and San Diego, Dec. 3 (Korea Bizwire) - Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced interim data from a Phase 2 study evaluating pracinostat, a histone deacetylase [...]